Objective To improve the compound--Gankang granules(GKGs) on the odor,taste and efficacy by decreasing 30% components and to prepare the new compound GKGs based on the Traditional Chinese Medicine Theory.Methods The d...Objective To improve the compound--Gankang granules(GKGs) on the odor,taste and efficacy by decreasing 30% components and to prepare the new compound GKGs based on the Traditional Chinese Medicine Theory.Methods The drug was extracted by the optimized technology ascertained in the previous studies.The cytotoxicity of the prescriptions was tested by MTT [3-(4,5-di-methylthiazol-2-yl)-2,5-diphenyl tetrazolium] assay,and the anti-hepatitis B virus(anti-HBV) activity was determined by ELISA(enzyme-linked-immunosorbent assay) in vitro.Results In the human HBV-transfected liver cell line HepG2.2.15,the new GKGs did not show any cytotoxicity with the 50% cytotoxic concentration(TC50) of 7.131,1.756 and 1.809 mg/mL after treatment for 3,6 and 9 days respectively,which was obviously higher than that in the human liver cell line HepG2.Moreover,they effectively suppressed the secretion of the HBV antigens with the TI of 8.519,5.730 and 7.066 for HBsAg,and 1.723,12.839 and 47.65 for HBeAg at day 3,6 and 9 respectively.This effect was as good as that of the old GKGs.On the 6th and 9th day,the rate of HBeAg inhibition exceeded 90% even with the concentration as low as 0.16 mg/mL,which was similar to that of the old GKGs.Conclusions These results reflect that the new GKGs precede the old GKGs by much lower cytotoxicity with similar anti-HBV activity,which provides reliable evidences for further pharmacological and toxicological exploration on this new compound.展开更多
基金grants from Scientific and Technological Plan ofChangsha City (No. K0902033-31)Scientific and Technologi-cal Plan of Hunan Province (No. 2009FJ3209)
文摘Objective To improve the compound--Gankang granules(GKGs) on the odor,taste and efficacy by decreasing 30% components and to prepare the new compound GKGs based on the Traditional Chinese Medicine Theory.Methods The drug was extracted by the optimized technology ascertained in the previous studies.The cytotoxicity of the prescriptions was tested by MTT [3-(4,5-di-methylthiazol-2-yl)-2,5-diphenyl tetrazolium] assay,and the anti-hepatitis B virus(anti-HBV) activity was determined by ELISA(enzyme-linked-immunosorbent assay) in vitro.Results In the human HBV-transfected liver cell line HepG2.2.15,the new GKGs did not show any cytotoxicity with the 50% cytotoxic concentration(TC50) of 7.131,1.756 and 1.809 mg/mL after treatment for 3,6 and 9 days respectively,which was obviously higher than that in the human liver cell line HepG2.Moreover,they effectively suppressed the secretion of the HBV antigens with the TI of 8.519,5.730 and 7.066 for HBsAg,and 1.723,12.839 and 47.65 for HBeAg at day 3,6 and 9 respectively.This effect was as good as that of the old GKGs.On the 6th and 9th day,the rate of HBeAg inhibition exceeded 90% even with the concentration as low as 0.16 mg/mL,which was similar to that of the old GKGs.Conclusions These results reflect that the new GKGs precede the old GKGs by much lower cytotoxicity with similar anti-HBV activity,which provides reliable evidences for further pharmacological and toxicological exploration on this new compound.
